Prospective Multi-center Dosimetry Study of Low-dose Iodine-125 Prostate Brachytherapy Performed After Transurethral Resection

Overview

Journal J Contemp Brachytherapy

Date 2013 Jul 24

PMID 23878549

Citations 11

Authors

Carl Salembier

Alex Rijnders

Ann Henry

Peter Niehoff

Frank Andre Siebert

Peter Hoskin

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate in a multicenter setting the ability of centers to perform pre-implant permanent prostate brachytherapy planning, fulfilling dosimetric goals and constraints based on the Groupe de Curiethérapie-European Society for Radiotherapy and Oncology guidelines in the setting of implantation after prior prostate transurethral resection (TURP).

Material And Methods: A reference transrectal ultrasound image set of the prostate gland from a patient who had undergone TURP was used. Contouring of the prostate, clinical target volume and organs at risk was performed by the coordinating center. Goals and constraints regarding the dosimetry were defined.

Results: Seventeen of twenty-five centers invited to participate were able to import the Digital Imaging and Communications in Medicine-images into their planning computer and plan the implant using the defined guidelines. All centers were able to plan treatment, and achieve the recommended objectives and constraints. However, sector analysis has shown a risk of under-dosage in the anterior part of the prostate.

Conclusions: Correct pre-implantation planning with adherence to protocol guidelines and in compliance with defined dosimetric constraints seems feasible in a post-TURP setting, at least on a theoretical basis. A prospective study evaluating the outcome of prostate brachytherapy performed after TURP can therefore be undertaken with an expectation of a correct dosimetry in the multicenter setting.

Citing Articles

Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: Efficacy and late urinary toxicity according to transurethral resection of the prostate history.

Galienne M, Risbourg S, Lacornerie T, Taillez A, Lartigau E, Barthoulot M Clin Transl Radiat Oncol. 2024; 46:100779.

PMID: 38681137 PMC: 11047194. DOI: 10.1016/j.ctro.2024.100779.

A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial.

Salembier C, Henry A, Pieters B, Hoskin P J Contemp Brachytherapy. 2020; 12(1):1-5.

PMID: 32190063 PMC: 7073343. DOI: 10.5114/jcb.2020.92913.

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes.

Chao M, Spencer S, Guerrieri M, Ding W, Goharian M, Ho H J Contemp Brachytherapy. 2018; 10(2):155-161.

PMID: 29789764 PMC: 5961530. DOI: 10.5114/jcb.2018.75600.

The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy.

Echevarria M, Naghavi A, Venkat P, Abuodeh Y, Chevere C, Yamoah K J Contemp Brachytherapy. 2016; 8(5):386-390.

PMID: 27895679 PMC: 5116453. DOI: 10.5114/jcb.2016.63357.

Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Longterm results.

Prada P, Anchuelo J, Garcia Blanco A, Paya G, Cardenal J, Acuna E Int Braz J Urol. 2016; 42(1):47-52.

PMID: 27136466 PMC: 4811225. DOI: 10.1590/S1677-5538.IBJU.2014.0531.

References

McElveen T, Waterman F, Kim H, Dicker A . Factors predicting for urinary incontinence after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004; 59(5):1395-404. DOI: 10.1016/j.ijrobp.2004.01.050. View

Stone N, Ratnow E, Stock R . Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol. 2000; 6(2):123-7. View

Cesaretti J, Stone N, Stock R . Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Int J Radiat Oncol Biol Phys. 2004; 60(2):648-53. DOI: 10.1016/j.ijrobp.2004.05.070. View

Wallner K, Lee H, Wasserman S, dAttoli M . Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys. 1997; 37(3):565-9. DOI: 10.1016/s0360-3016(96)00570-6. View

Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A . Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007; 83(1):3-10. DOI: 10.1016/j.radonc.2007.01.014. View

Blasko J, RAGDE H, Grimm P . Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 1991; 137:113-8. View

Matzinger O, Poortmans P, Giraud J, Maingon P, Budiharto T, van den Bergh A . Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. Radiother Oncol. 2008; 90(3):285-90. DOI: 10.1016/j.radonc.2008.10.022. View

Seddon B, Bidmead M, Wilson J, Khoo V, Dearnaley D . Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiother Oncol. 2000; 56(1):73-83. DOI: 10.1016/s0167-8140(00)00191-2. View

Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L . ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000; 57(3):315-21. DOI: 10.1016/s0167-8140(00)00306-6. View

10.

Davis B, Horwitz E, Lee W, Crook J, Stock R, Merrick G . American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012; 11(1):6-19. DOI: 10.1016/j.brachy.2011.07.005. View

11.

Fiorino C, Reni M, Bolognesi A, Cattaneo G, Calandrino R . Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiother Oncol. 1998; 47(3):285-92. DOI: 10.1016/s0167-8140(98)00021-8. View

12.

Moran B, Stutz M, Gurel M . Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys. 2004; 59(2):392-6. DOI: 10.1016/j.ijrobp.2003.10.013. View

13.

Gao Z, Wilkins D, Eapen L, Morash C, Wassef Y, Gerig L . A study of prostate delineation referenced against a gold standard created from the visible human data. Radiother Oncol. 2007; 85(2):239-46. DOI: 10.1016/j.radonc.2007.08.001. View

14.

Nag S, Beyer D, Friedland J, Grimm P, Nath R . American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999; 44(4):789-99. DOI: 10.1016/s0360-3016(99)00069-3. View

15.

Cazzaniga L, Marinoni M, Bossi A, Bianchi E, Cagna E, Cosentino D . Interphysician variability in defining the planning target volume in the irradiation of prostate and seminal vesicles. Radiother Oncol. 1998; 47(3):293-6. DOI: 10.1016/s0167-8140(98)00028-0. View

16.

Smith S, Wallner K, Merrick G, Butler W, Sutlief S, Grimm P . Interpretation of pre- versus postimplant TRUS images. Med Phys. 2003; 30(5):920-4. DOI: 10.1118/1.1568980. View

17.

Rosewall T, Kong V, Vesprini D, Catton C, Chung P, Menard C . Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses. Radiother Oncol. 2009; 90(3):325-30. DOI: 10.1016/j.radonc.2008.11.015. View

18.

De Brabandere M, Hoskin P, Haustermans K, Van Den Heuvel F, Siebert F . Prostate post-implant dosimetry: interobserver variability in seed localisation, contouring and fusion. Radiother Oncol. 2012; 104(2):192-8. DOI: 10.1016/j.radonc.2012.06.014. View